+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      The Influence of Melatonin Administered Subcutaneously, Intravenously, or Intraocularly upon Ovulation in the PMS-Treated Immature Rat



      S. Karger AG

      Ovulation, Melatonin, Intraocular, Subcutaneous, Pregnant mare serum (PMS), Intravenous

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Immature female rats were induced to ovulate 72 h after an injection of pregnant mare serum (PMS). Melatonin, a compound synthesized in the pineal gland, was injected by three different routes: subcutaneously, intravenously, and intraocularly. In experiment 1, 10 µg of melatonin, injected at 12, 2, and 4 p.m. on day 2 after PMS, was ineffective in preventing ovulation, whether injected subcutaneously or into the eyeball. However, 100 µg of melatonin placed into the eyeball reduced the number of rats ovulating, as well as ovarian weights, relative to controls. Uterine weights of these rats were increased compared to controls. In experiment 2, the intraocular injection of 100 µg of melatonin inhibited ovulation in the greatest number of rats, compared to the intravenous or subcutaneous routes. Experiment 3 was a repeat of experiment 2, with comparable results. In experiment 4, with a dosage of 75 µg of melatonin, the intraocular administration appeared to be the most effective route for inhibiting ovulation. In experiment 5, subcutaneous administration of 50 µg of melatonin was completely ineffective in blocking ovulation or altering ovarian weights. The intraocular injection, however, significantly reduced ovarian weights.

          Related collections

          Author and article information

          S. Karger AG
          19 March 2008
          : 12
          : 6
          : 354-361
          Departments of Anatomy and Medicine, University of Rochester, School of Medicine and Dentistry, Rochester, N.Y.
          122184 Neuroendocrinology 1973;12:354–361
          © 1973 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8


          Comment on this article